Figures & data
Table 1 Antimicrobial Susceptibility of Clinical S. aureus Strains Isolated from Patients with DFUs
Figure 1 Antimicrobial activity of surfactin against ATCC 25923 and a clinical MRSA isolated from a patient with DFUs. (A and B) Surfactin inhibited the growth of ATCC 25923 and SA 452 in a dose-dependent manner during a 24-h exposure period. (C and D) Surfactin had a dose-dependent inhibitory effect on ATCC 25923 and SA 452 biofilm formation. All data are presented as mean±SD; ***P < 0.001.
Figure 2 Transmission electron microscopy images of ATCC 25923. (A and B) ATCC 25923 treated with 5×MIC surfactin for 1 h. Green arrows indicate dead cells, and blue arrow indicates damaged cell structure. (C and D) Control, cells treated with 0.05% DMSO. Scale bars, 200 nm (left), 100 nm (right).
Table 2 Antimicrobial Activity of the Combination between Surfactin and Conventional Antibiotics Against ATCC 25923 and Clinical MRSA Isolated from Patients with DFUs
Figure 3 Penicillinase inhibitory activity of surfactin. (A) Inhibition of penicillinase by surfactin and (B) by clavulanate potassium.
Table 3 MPCs of Surfactin and Oxacillin in Combinations with Different Proportions for ATCC 25923 and Clinical MRSA Isolated from Patients with DFUs